Received Feb 20, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
stiffness; upper body muscle aches; slight headache; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of stiffness in a patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis. On 13-FEB-2025, the patient received Arexvy. In FEB-2025, an unknown time after receiving Arexvy, the patient experienced stiffness (Verbatim: stiffness), muscle pain (Verbatim: upper body muscle aches) and headache (Verbatim: slight headache). The outcome of the stiffness, muscle pain and headache were not reported. It was unknown if the reporter considered the stiffness, muscle pain and headache to be related to Arexvy. It was unknown if the company considered the stiffness, muscle pain and headache to be related to Arexvy. Additional Information: GSK Receipt Date: 14-FEB-2025 This case was reported by a patient via interactive digital media. Consumer reported that he/she experience upper body muscle aches, stiffness, slight headache after injection on February 13 2025 The follow-up could not be possible as no contact details were available.